Screener
Gyre Therapeutics, Inc. GYRE Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $740K-21.4% | —— | —— | —— | $941K+169% | ||
| $29.11M-2.1% | $22.52M+2.1% | $37.2M+33.4% | $30.56M+19.9% | $29.73M+17.9% | ||
| $2.21M+91.9% | $1.23M+37.2% | $1.74M+48.1% | $1.63M+69.9% | $1.15M+49.5% | ||
| $26.9M-5.9% | $21.29M+0.6% | $35.45M+32.8% | $28.94M+18.0% | $28.58M+16.9% | ||
| 92.4%-3.7pp | 94.6%-1.4pp | 95.3%-0.5pp | 94.7%-1.6pp | 96.1%-0.8pp | ||
| —— | $6.74M+118% | $4.82M+29.7% | $2.36M-14.8% | $8.35M+149% | ||
| $13.75M-9.5% | $14.14M+30.4% | $23.82M+41.3% | $15.33M+11.9% | $15.2M+5.4% | ||
| $7.87M+8.1% | $7.22M+45.7% | $6.7M+22.6% | $4.32M+13.0% | $7.28M+113% | ||
| $43.47M+35.9% | $31.87M+61.1% | $37.08M+36.3% | $23.64M+11.2% | $31.97M+45.1% | ||
| -$14.36M-541% | -$9.36M-512% | $118K-82.3% | $6.93M+63.6% | -$2.24M-170% | ||
| -49.3%-41.8pp | -41.5%-51.8pp | 0.3%-2.1pp | 22.7%+6.0pp | -7.5%-20.2pp | ||
| -$943K-93.2% | $29K-72.9% | -$2.19M-34.3% | $727K+1,069% | -$488K-578% | ||
| -$14.43M-816% | -$9.24M-299% | $3.75M+385% | $7.63M+94.1% | -$1.58M-126% | ||
| -$164K-125% | $621K-31.1% | $1.3M+540% | $1.69M+57.6% | $662K-55.8% | ||
| -$11.66M-471% | -$8.69M-422% | $763K— | $3.61M+221% | -$2.04M-158% | ||
| -40.1%-33.2pp | -38.6%-50.8pp | 2.1%+2.1pp | 11.8%+7.4pp | -6.9%-20.9pp | ||
| -$0.12-300% | -$0.10— | $0.02— | $0.03+200% | -$0.03-400% | ||
| -$12.88M-946% | -$8.68M-409% | $774K-31.3% | $7.21M+54.0% | -$1.23M-136% | ||
| -44.3%-40.1pp | -38.6%-51.3pp | 2.1%-2.0pp | 23.6%+5.2pp | -4.1%-17.7pp | ||
| -$14.36M-541% | -$9.36M-512% | $118K-82.3% | $6.93M+63.6% | -$2.24M-170% |
FAQ
- What is Gyre Therapeutics, Inc.'s revenue?
- Gyre Therapeutics, Inc. (GYRE) generated $119.4M in revenue over the trailing twelve months, up 13.5% year over year.
- Is Gyre Therapeutics, Inc. profitable?
- Gyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $16.0M over the trailing twelve months, a -13.4% net margin.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gross margin is 94.3% and operating margin is -14.0%, with a -13.4% net margin.
- What is Gyre Therapeutics, Inc.'s earnings per share?
- Gyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.17.
- Where does Gyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
